CONSOLIDATED BALANCE SHEETS (USD $) In Millions, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2011
Current Assets:
Cash and cash equivalents	$ 1,656	$ 5,776
Marketable securities	1,173	2,957
Receivables	3,083	3,743
Inventories	1,657	1,384
Deferred income taxes	1,597	1,200
Prepaid expenses and other	355	258
Total Current Assets	9,521	15,318
Property, plant and equipment	5,333	4,521
Goodwill	7,635	5,586
Other intangible assets	8,778	3,124
Deferred income taxes	203	688
Marketable securities	3,523	2,909
Other assets	904	824
Total Assets	35,897	32,970
Current Liabilities:
Short term borrowings and current portion of long-term debt		115
Short-term borrowings and current portion of long-term debt	826
Accounts payable	2,202	2,603
Accrued expenses	2,573	2,791
Deferred income	825	337
Accrued rebates and returns	1,054	1,170
U.S. and foreign income taxes payable	193	167
Dividends payable	606	597
Total Current Liabilities	8,279	7,780
Pension, postretirement, and postemployment liabilities	1,882	2,017
Deferred income	4,024	866
U.S. and foreign income taxes payable	648	573
Deferred income taxes	383	107
Other liabilities	475	384
Long-term debt	6,568	5,376
Total Liabilities	22,259	17,103
Commitments and contingencies (Note 21)
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 5,117 in 2012 and 5,268 in 2011, liquidation value of $50 per share	0	0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2012 and 2011	221	220
Capital in excess of par value of stock	2,694	3,114
Accumulated other comprehensive loss	(3,202)	(3,045)
Retained earnings	32,733	33,069
Less cost of treasury stock - 570 million common shares in 2012 and 515 million in 2011	(18,823)	(17,402)
Total Bristol-Myers Squibb Company Shareholders' Equity	13,623	15,956
Noncontrolling interest	15	(89)
Total Equity	13,638	15,867
Total Liabilities and Equity	$ 35,897	$ 32,970